Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trialCNBC • 08/19/26
An experimental mRNA-based cancer vaccine succeeded in preventing melanoma from coming back or spreading in a large study, partners Merck and Moderna said.WSJ • 08/19/26
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV MelanomaBusiness Wire • 08/19/26
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely SuccessZacks Investment Research • 08/18/26
Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical TrialsBusiness Wire • 08/13/26
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequencesCNBC • 08/11/26
MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?Zacks Investment Research • 08/11/26
Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?Zacks Investment Research • 08/06/26
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second SeasonBusiness Wire • 08/06/26
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/04/26